We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Effects of novel glucose-lowering drugs on the COVID-19 patients with diabetes: A network meta-analysis of clinical outcomes.
- Authors
Yang, Yang; Zhao, Ling; Wang, Yeying; Liu, Chengjiang; Ke, Tingyu
- Abstract
Objective: This study aimed to assess the effects of sodium-glucose co-transporter inhibitors (SGLT2i), glucagon-like peptide-1 receptor agonists (GLP-1RA), and dipeptidyl peptidase-4 inhibitors (DPP4i) on individuals subjected to diabetes and COVID-19. Methods: PubMed, Embase, Web of Science, and Cochrane Library were systematically searched to cover studies (except for case reports and review studies) published until August 30, 2022. The primary outcome was the mortality of people with diabetes and COVID-19. The secondary outcomes comprised the requiring intensive care unit (ICU) admission and mechanical ventilation. Two reviewers independently screened studies, abstracted data, and assessed risk-of-bias. Furthermore, the network meta-analyses (NMA) were conducted. Results: A total of 12 trials were involved in the analysis. The OR and 95% CI of mortality for SGLT2i compared with SGLT2i + GLP-1RA and DPP4i reached 0.41 (0.17,0.97) and 0.69 (0.49,0.98), respectively. The OR and 95% CI of requiring mechanical ventilation for SGLT2i compared with the DPP4i reached 0.85 (0.75,0.97). Conclusions: As revealed by the result of this study, SGLT2i is associated with the lower mortality rate in people with diabetes and COVID-19 among novel glucose-lowering drugs. And SGLT2i is linked to lower requiring mechanical ventilation. These findings can have a large impact on clinicians' decisions amid the COVID-19 pandemic.
- Subjects
CHINA; MORTALITY risk factors; GLUCAGON-like peptide-1 agonists; COMBINATION drug therapy; MEDICAL information storage &; retrieval systems; RESEARCH funding; PATIENTS; ENZYME inhibitors; HOSPITAL admission &; discharge; HYPOGLYCEMIC agents; META-analysis; MEDLINE; ODDS ratio; SODIUM-glucose cotransporter 2 inhibitors; DRUG efficacy; MEDICAL databases; INTENSIVE care units; ARTIFICIAL respiration; ONLINE information services; CONFIDENCE intervals; COVID-19; DIABETES
- Publication
International Journal of Diabetes in Developing Countries, 2024, Vol 44, Issue 3, p426
- ISSN
0973-3930
- Publication type
Article
- DOI
10.1007/s13410-023-01228-x